{"url":"https://lda.senate.gov/api/v1/filings/a50314d0-11b0-4a64-bc3e-5fc321f2bc0e/","filing_uuid":"a50314d0-11b0-4a64-bc3e-5fc321f2bc0e","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2015,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/a50314d0-11b0-4a64-bc3e-5fc321f2bc0e/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Chris Jones","dt_posted":"2016-01-15T13:05:24.687000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 Pennsylvania Ave NW","registrant_address_2":"Suite 230","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400446141,"url":"https://lda.senate.gov/api/v1/registrants/400446141/","house_registrant_id":null,"name":"FERGUSON STRATEGIES, LLC","description":"Government affairs and public policy consulting firm.","address_1":"801 Pennsylvania Ave NW","address_2":"Suite 230","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004-2697","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRIS JONES","contact_telephone":"+1 202-861-1617","dt_updated":"2022-04-06T16:07:13.725346-04:00"},"client":{"id":191004,"url":"https://lda.senate.gov/api/v1/clients/191004/","client_id":265,"name":"ADVAXIS, INC.","general_description":"Biotechnology manufacturer","client_government_entity":false,"client_self_select":null,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-07-20"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 6, the \"21st Century Cures Act.\"\nPolicy issues relating Public Law No. 112-144, the \"Food and Drug Administration Safety and Innovation Act,\" specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":47998,"prefix":null,"prefix_display":null,"first_name":"CHRIS","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":51135,"prefix":null,"prefix_display":null,"first_name":"ADAM","nickname":null,"middle_name":null,"last_name":"HIGGINS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}